Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1611 1614 4100
This examiner grants 100% of resolved cases
Makenna Ryleigh Miller is an examiner in Tech Center 4100 and Art Unit 1611, with 2 resolved cases. Both of these cases resulted in an allowance, leading to a 100.0% allowance rate. The median days to allowance for these resolutions was 1259, which is a relatively long timeline for applicants to navigate before reaching a final grant.
The interview lift is 0.0%, though this is based on the very limited data of 2 resolved cases. Since the allowance rate is already at 100.0%, the lift metric does not currently show any increase in success probability from interviewing. Practitioners should view these figures as preliminary given the minimal case volume and the specific nature of the cases handled in Art Unit 1611.
With only 2 resolved cases, the 1259-day median pendency and 100.0% allowance rate provide a narrow window into Miller's practice. The absence of an interview lift may change as more cases are resolved and the examiner's experience grows in Tech Center 4100. For now, the data suggests a successful, albeit slow, track record that practitioners should monitor as more resolutions are recorded.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18650661 | INJECTABLE COMPOSITIONS AND RELATED METHODS | Non-Final OA | Boston Scientific Scimed, Inc. |
| 18855176 | METHOD FOR PRODUCING OCTACALCIUM PHOSPHATE MOLDED ARTICLE COMPOUNDED WITH BIOCOMPATIBLE POLYMER | Non-Final OA | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY |
| 18847363 | METHOD FOR PRESERVING SOLID COMPOSITION THAT CONTAINS FORM II TYPE CRYSTALS OF REDUCED COENZYME Q10, AND PACKING THAT CONTAINS SAID SOLID COMPOSITION | Non-Final OA | KANEKA CORPORATION |
| 18993836 | NEW AGROCHEMICAL FORMULATIONS | Non-Final OA | BASF SE |
| 18785831 | PROCESS FOR TREATING KERATINOUS MATERIAL, COMPRISING THE MIXING OF AT LEAST TWO AGENTS (A) AND (B) | Non-Final OA | Henkel AG & Co. KGaA |
| 18034111 | STABLE ANTIMICROBIAL FORMULATION CONCENTRATE | Non-Final OA | Kimberly-Clark Worldwide, Inc. |
| 18460146 | COMPOSITION FOR PRODUCING A BONE REPLACEMENT MATERIAL, METHOD FOR PRODUCING A PHARMACEUTICAL EXCIPIENT, PHARMACEUTICAL EXCIPIENT, AND USE THEREOF | Non-Final OA | Heraeus Medical GmbH |
| 18540979 | EYELASH COATING COMPOSITIONS FOR FALSE EYELASHES | Final Rejection | L'OREAL |
| 18902326 | Personal Care Compositions | Non-Final OA | Colgate-Palmolive Company |
| 18395221 | FORMULATIONS WITH REDUCED LEVELS OF VOLATILE ORGANIC COMPOUNDS | Final Rejection | S. C. Johnson & Son, Inc. |
| 18852696 | FUNCTIONALIZED CORE-SHELL NANOGEL SCAVENGER FOR IMMUNE MODULATION THERAPY | Non-Final OA | The Research Foundation for the State University of New York |
| 18729490 | BIODEGRADABLE MICROCAPSULES WITH IMPROVED STORAGE STABILITY, PROCESS FOR PREPARING THE SAME AND METHOD OF USE THEREOF | Non-Final OA | ISP Investments LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy